Satsuma Pharmaceuticals to Present Two Posters at the American Headache Society’s Annual Scientific Meeting Hosted via a Virtual Meeting Platform - Seite 3

This press release discusses STS101, a product candidate that is in clinical development, and which has not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of STS101 for the therapeutic use for which STS101 is being studied.

INVESTOR AND CORPORATE CONTACTS: 

Corey Davis, PhD
LifeSci Advisors, LLC
[e-mail]

Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
[e-mail]